NeuroDerm Announces Extraordinary General Meeting of Shareholders for Ratification of Election of External Directors and Adoption of Compensation Policy
19 janv. 2015 11h15 HE
|
NeuroDerm Ltd.
REHOVOT, Israel, Jan. 19, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical-stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced...
NeuroDerm Announces Topline Results of Phase IIa Pharmacokinetic Study of ND0612H and ND0612L, Continuous, Subcutaneously Delivered Levodopa/Carbidopa for the Treatment of Parkinson's Disease
30 déc. 2014 07h00 HE
|
NeuroDerm Ltd.
REHOVOT, Israel, Dec. 30, 2014 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical-stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced...
NeuroDerm Announces Third Quarter 2014 Financial Results and Provides a Corporate Update
18 déc. 2014 07h00 HE
|
NeuroDerm Ltd.
REHOVOT, Israel, Dec. 18, 2014 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced...
NeuroDerm CEO to Present at Oppenheimer Healthcare Conference on December 10, 2014
05 déc. 2014 08h53 HE
|
NeuroDerm Ltd.
REHOVOT, Israel, Dec. 5, 2014 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that...
NeuroDerm Announces Pricing of Initial Public Offering
14 nov. 2014 00h27 HE
|
NeuroDerm Ltd.
REHOVOT, Israel, Nov. 14, 2014 (GLOBE NEWSWIRE) -- NeuroDerm Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced the pricing of...